Literature DB >> 9699672

The murine Fhit locus: isolation, characterization, and expression in normal and tumor cells.

Y Pekarsky1, T Druck, M G Cotticelli, M Ohta, J Shou, J Mendrola, J C Montgomery, A M Buchberg, L D Siracusa, G Manenti, L Y Fong, T A Dragani, C M Croce, K Huebner.   

Abstract

The murine Fhit locus maps near the centromere nu proximal Ptprg locus on mouse chromosome 14. The cDNA sequence and structure are similar to those of the human gene, with exons 5-9 encoding the protein. The predominant mRNA in the tissues and cell lines tested was an alternatively spliced form missing exon 3. Most murine cell lines tested, including lines established from normal mouse embryos and tumors, expressed very low or undetectable levels of Fhit mRNA. Most normal mouse tissues expressed wild-type Fhit mRNA, whereas approximately 40% of murine lung carcinomas expressed wild-type and aberrant Fhit RT-PCR products that lacked various exons. Several tumorigenic mouse cell lines exhibited homozygous deletions of Fhit exons. We conclude that the murine Fhit gene, like its human counterpart, is a target of alterations involved in murine carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9699672

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Hint, Fhit, and GalT: function, structure, evolution, and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferases.

Authors:  Charles Brenner
Journal:  Biochemistry       Date:  2002-07-23       Impact factor: 3.162

2.  Sequence conservation at human and mouse orthologous common fragile regions, FRA3B/FHIT and Fra14A2/Fhit.

Authors:  T Shiraishi; T Druck; K Mimori; J Flomenberg; L Berk; H Alder; W Miller; K Huebner; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

3.  FHIT gene therapy prevents tumor development in Fhit-deficient mice.

Authors:  K R Dumon; H Ishii; L Y Fong; N Zanesi; V Fidanza; R Mancini; A Vecchione; R Baffa; F Trapasso; M J During; K Huebner; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

Review 4.  WWOX: a fragile tumor suppressor.

Authors:  Morgan S Schrock; Kay Huebner
Journal:  Exp Biol Med (Maywood)       Date:  2014-12-22

5.  The tumor spectrum in FHIT-deficient mice.

Authors:  N Zanesi; V Fidanza; L Y Fong; R Mancini; T Druck; M Valtieri; T Rüdiger; P A McCue; C M Croce; K Huebner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

6.  Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes.

Authors:  Y Pekarsky; C Hallas; M Isobe; G Russo; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

7.  Influence of FHIT on benzo[a]pyrene-induced tumors and alopecia in mice: chemoprevention by budesonide and N-acetylcysteine.

Authors:  Roumen Balansky; Francesco D'Agostini; Gancho Ganchev; Alberto Izzotti; Barbara Di Marco; Ronald A Lubet; Nicola Zanesi; Carlo M Croce; Silvio De Flora
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-03       Impact factor: 11.205

8.  Muir-Torre-like syndrome in Fhit-deficient mice.

Authors:  L Y Fong; V Fidanza; N Zanesi; L F Lock; L D Siracusa; R Mancini; Z Siprashvili; M Ottey; S E Martin; T Druck; P A McCue; C M Croce; K Huebner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

9.  Reduced Fhit protein expression in nickel-transformed mouse cells and in nickel-induced murine sarcomas.

Authors:  Renata Kowara; Konstantin Salnikow; Bhalchandra A Diwan; Robert M Bare; Michael P Waalkes; Kazimierz S Kasprzak
Journal:  Mol Cell Biochem       Date:  2004-01       Impact factor: 3.396

10.  Fragile site orthologs FHIT/FRA3B and Fhit/Fra14A2: evolutionarily conserved but highly recombinogenic.

Authors:  Ayumi Matsuyama; Takeshi Shiraishi; Francesco Trapasso; Tamotsu Kuroki; Hansjuerg Alder; Masaki Mori; Kay Huebner; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.